placebo + lansoprazole

This combination refers to the control arm intervention used in clinical trials led by Ranjan Dohil, specifically for the treatment of pediatric eosinophilic esophagitis (EoE). It consists of a placebo, often formulated as an oral viscous solution to match investigational topical corticosteroids like budesonide, administered alongside the proton pump inhibitor (PPI) lansoprazole. Lansoprazole is a small molecule that suppresses gastric acid secretion by covalently binding to and inhibiting the H+/K+-ATPase enzyme system (the proton pump) in gastric parietal cells. In the context of EoE research, this combination is used to isolate the therapeutic effects of investigational anti-inflammatory agents from the effects of standard acid-suppression therapy, which can independently reduce esophageal eosinophilia in some patients.

Brand names

placebo + Prevacid

Other names

placebo plus lansoprazoleplacebo plus Prevacid